Therapeutic Response
CD20 + status confers therapeutic sensitivity to Cyclophosphamide in combination with Doxorubicin, Etoposide, Prednisolone, Rituximab, and Vincristine in patients with Diffuse Large B-Cell Lymphoma.
Statements
| Source and description |
|---|